aBLA Filing Intelligence & Biosimilar Opportunity

Enjaymo

Sutimlimab-Jome

Immunomodulators

Injection Injectable

Approval Date

04-Feb-22

Data Exclusivity Expiry

04-Feb-26

Market Exclusivity Expiry

04-Feb-34

Commercial snapshot

Market performance & projections

Revenue ($M)

165

CAGR (%)

0.2212

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

283

2027

317

2028

343

2029

367

2030

383

2031

395

2032

403

Molecule profile

Details & specifications

Molecule

Sutimlimab-Jome

Innovator

RECORDATI RARE DISEASES, INC.

Dosage Form

Injection Injectable

Strength

1,100 mg/22 mL (50 mg/mL)

Therapeutic Category

Immunomodulators

Usage

To decrease the need for red blood cell transfusion due to hemolysis in cold agglutinin disease

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.